Home » NEW DATA HIGHLIGHT ANTI-HCV ACTIVITY OF INVESTIGATIONAL ORAL HEPATITIS C PROTEASE INHIBITOR VX-950
NEW DATA HIGHLIGHT ANTI-HCV ACTIVITY OF INVESTIGATIONAL ORAL HEPATITIS C PROTEASE INHIBITOR VX-950
Vertex Pharmaceuticals Incorporated
today announced that researchers will present new data supporting clinical development
of VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor
being developed for the treatment of hepatitis C, at the 41st Annual Meeting of
the European Association for the Study of the Liver (EASL) in Vienna. Two abstracts
will be presented on Thursday, April 27 based on a clinical trial originally conducted
in 2005.
PR
Newswire
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct